Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68788-8140

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68788-8140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

A pharmacokinetic fold change graph illustrating the impact of various interacting drugs on venlafaxine. The chart plots Cmax and AUC changes relative to a reference value for ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium, with recommended clinical cautions or dosage adjustments noted alongside.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

A PK fold change chart detailing the interaction of various drugs with Venlafaxine Hydrochloride, showing Cmax and AUC changes relative to a reference value. The graph includes interacting drugs like ethanol, diazepam, alprazolam, and others, with 90% confidence intervals and recommendations such as dose adjustments or clinical significance notes.*

FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

A forest plot chart depicting pharmacokinetic (PK) changes of venlafaxine in special populations. The chart shows fold changes with 90% confidence intervals for analytes venlafaxine and ODV across multiple conditions including hepatic impairment (cirrhosis, mild, moderate), renal impairment (mild/moderate, hemodialysis), CYP2D6 polymorphism, age over 60 years, and gender. Recommendations for dose adjustments are noted alongside the data points.*

FDA Label Image

Venlafaxine HCl Extended-release Capsules 75mg (Venlafaxine Fig4)

Label for Venlafaxine Hydrochloride Extended-Release Capsules 75 mg, a generic for Effexor ER. The label indicates an oral capsule dosage form with extended release, manufactured by Aurobindo Pharma Limited. It includes storage instructions, patient caution, and space for lot, batch, and expiration details. The label is primarily white with yellow highlighted instruction sections in English and Spanish and features the Preferred Pharmaceuticals, Inc. logo.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical structure diagram of the active ingredient Venlafaxine Hydrochloride, showing its molecular framework including a cyclohexane ring, methoxyphenyl group, and dimethylaminoethyl side chain with associated hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.